超抗原活化人淋巴细胞疫苗在SCID鼠体内抗人脑胶质瘤研究

Preliminary study on anti-tumor effects of superantigen activated human lymphocytes vaccine against glioma in SCID mice

目的 探讨超抗原SEC激活的人外周血单个核细胞 (HuPBMC)在动物体内抗人脑胶质瘤的疗效。方法 建立人脑胶质瘤和转输人外周血单个核细胞于SCID小鼠体的人肿瘤 人淋巴细胞的嵌合模型 ,并用SEC治疗之。结果 在肿瘤增殖曲线 ,增殖比、荷瘤鼠生存期 ,瘤组织病理形态等多项指标证实SEC +HuPBMC组的疗效明显优于单纯SEC和单纯HuPBMC组。结论 SEC作为免疫治疗赋活剂 ,在荷人脑肿瘤·人淋巴细胞SCID鼠体内的联合免疫治疗作用优于任何单一治疗组 ,为其临床应用奠定了理论基础。

Objective To evaluate the effectiveness of staphylococcal enterotoxin C(SEC) activated human peripheral mononuclear cells against human glioma in SCID mice. Methods Human lymphocytes were transplanted to human glioma-bearing SCID mice to establish the chimeric model of human tumor and lymphocytes. SEC was applied for tumor treatment. Results The treatment effect of SEC+HuPBMC group was obviously better than SEC group and HuPBMC group, this was proved by tumor proliferation curve, proliferation ratio, survival duration of tumor-bearing mice and pathological findings of tumor tissue. Conclusion As an immuno-activator, SEC enhanced significantly the attacking effects against glioma, especially in the combined immunotherapy group in tumor-human lymphocytes-bearing SCID mice. The treatment effect of the combined group was better than any other single treatment group. This article offered the theoretical references for clinical application of SEC.